Home Nav
Nextech Invest Logo

Global Oncology Investment Expertise

We are a global investment advisor in healthcare with a focus on oncology. Nextech is run by an experienced team of industry experts and supported by key opinion leaders in oncology.

We deploy our expertise to invest equity in cancer companies with game changing discoveries in the fields of therapeutics, medical technologies and diagnostics.

Executive Management
Scientific Advisory Board
Executive Management
Executive Management

Portfolio Companies

Game Changing Cancer Companies

  • Agensys

    Full Exit

    Fully human antibody drug conjugates for pancreatic cancer.

  • Blueprint

    IPO

    Highly selective kinase inhibitors for genomically defined cancer subsets

  • Ganymed

    Full Exit

    Ideal monoclonal antibodies for cancer treatment.

  • ImaginAB

    Clinical Phase II

    Antibody fragments for imaging of cancer.

  • Jounce Therapeutics

    Preclinical

    Immunotherapeutics to create highly durable cancer treatments

  • Kura Oncology

    Clinical Phase II

    Small molecules that target cancer signaling pathways

  • MacroGenics

    Partial exit

    Antibodies for cancer immunotherapy

  • Molecular MD

    Market

    Cancer genotyping for targeted cancer therapies.

  • Palyon

    Full Exit

    Implantable drug pumps for palliative care and diabetes.

  • Peloton

    Clinical Phase I

    Small-molecule programs with a distinct target and mechanism of action.

  • Sunesis

    Partial exit

    Small molecules for acute myeloid leukemia.

  • Telormedix

    Sale of shares

    Targeted immunity in cancer and other diseases.

  • TetraLogic

    IPO

    Small molecule Smac mimetics for treatment of cancers.

  • TRACON

    IPO

    Antibodies targeting endoglin in cancer angiogenesis.

Corporate Presentation

Get it now.

  • 01.07.2015

    Tracon Pharmaceuticals announces IND filing...

  • 30.06.2015

    TetraLogic announces update on MDC clinical...

Corporate Presentation

Get it now.

Portfolio Companies

Game Changing Cancer Companies

  • Agensys

    Full Exit

    Fully human antibody drug conjugates for pancreatic cancer.

  • Blueprint

    IPO

    Highly selective kinase inhibitors for genomically defined cancer subsets

  • Ganymed

    Full Exit

    Ideal monoclonal antibodies for cancer treatment.

  • ImaginAB

    Clinical Phase II

    Antibody fragments for imaging of cancer.

  • Jounce Therapeutics

    Preclinical

    Immunotherapeutics to create highly durable cancer treatments

  • Kura Oncology

    Clinical Phase II

    Small molecules that target cancer signaling pathways

  • MacroGenics

    Partial exit

    Antibodies for cancer immunotherapy

  • Molecular MD

    Market

    Cancer genotyping for targeted cancer therapies.

  • Palyon

    Full Exit

    Implantable drug pumps for palliative care and diabetes.

  • Peloton

    Clinical Phase I

    Small-molecule programs with a distinct target and mechanism of action.

  • Sunesis

    Partial exit

    Small molecules for acute myeloid leukemia.

  • Telormedix

    Sale of shares

    Targeted immunity in cancer and other diseases.

  • TetraLogic

    IPO

    Small molecule Smac mimetics for treatment of cancers.

  • TRACON

    IPO

    Antibodies targeting endoglin in cancer angiogenesis.

  • Agensys

    Full Exit

    Fully human antibody drug conjugates for pancreatic cancer.

  • Blueprint

    IPO

    Highly selective kinase inhibitors for genomically defined cancer subsets

  • Ganymed

    Full Exit

    Ideal monoclonal antibodies for cancer treatment.

  • ImaginAB

    Clinical Phase II

    Antibody fragments for imaging of cancer.

  • Jounce Therapeutics

    Preclinical

    Immunotherapeutics to create highly durable cancer treatments

  • Kura Oncology

    Clinical Phase II

    Small molecules that target cancer signaling pathways

  • MacroGenics

    Partial exit

    Antibodies for cancer immunotherapy

  • Molecular MD

    Market

    Cancer genotyping for targeted cancer therapies.

  • Palyon

    Full Exit

    Implantable drug pumps for palliative care and diabetes.

  • Peloton

    Clinical Phase I

    Small-molecule programs with a distinct target and mechanism of action.

  • Sunesis

    Partial exit

    Small molecules for acute myeloid leukemia.

  • Telormedix

    Sale of shares

    Targeted immunity in cancer and other diseases.

  • TetraLogic

    IPO

    Small molecule Smac mimetics for treatment of cancers.

  • TRACON

    IPO

    Antibodies targeting endoglin in cancer angiogenesis.

Executive Management
Scientific Advisory Board
Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close